Original ArticlePharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations
Under a Creative Commons license
open access
Graphical abstract
Keywords
Apolipoprotein B
Alirocumab
Familial hypercholesterolemia
Clinical trial
LDL-C
PCSK9
Cited by (0)
Funding: This analysis was funded by Sanofi and Regeneron Pharmaceuticals, Inc.
© 2019 National Lipid Association. Published by Elsevier Inc.